We have applied our expertise in multivalency to discover product candidates and lead compounds in a number of therapeutic areas.

We believe that our lead product candidates have demonstrated in relevant preclinical models, potential advantages such as substantial increases in potency, duration of action and/or selectivity relative to existing medicines or potential medicines in late-stage clinical studies.

The table below summarizes the status of our most advanced product candidates for internal development or co-development. The table also includes the status of respiratory programs in which we have an economic interest that are being developed and commercialized by GSK pursuant to agreements with Theravance, Inc., now known as Innoviva, Inc.

Infectious Disease

Collaborators: Multiple (ex-U.S.)¹

Phase 1

Phase 2

Phase 3

Filed

Approved

Telavancin: Primary Bacteremia

Phase 1

Phase 2

Phase 3

Cefilavancin (TD-1792): Gram+ MRSA

Collaborators: R-Pharm (ex-U.S.)

Phase 1

Phase 2

Phase 3

TD-6450: HCV

Collaborators: Trek Therapeutics

Phase 1

Phase 2

Respiratory

Revefenacin (TD-4208): COPD

Collaborators: Mylan

Phase 1

Phase 2

Phase 3

Gastrointestinal

Axelopran (TD-1211): OIC

Phase 1

Phase 2

Axelopran (TD-1211)/Opioid FDC: Pain

Phase 1

Phase 2

Velusetrag: Gastroparesis

Collaborators: Alfa Wassermann (ex-U.S.)

Phase 1

Phase 2

TD-8954: ICU IV Prokinetic

Collaborators: Takeda

Phase 1

Phase 2

TD-1473: Ulcerative Colitis

Phase 1

Cardiovascular

TD-0714, TD-1439: Heart Failure, Chronic Kidney Disease

Phase 1

TD-9855: nOH

Phase 1

Economic Interests

Closed Triple (FF/UMEC/VI): COPD

Collaborators: GSK & Innoviva, Inc.²

Phase 1

Phase 2

Phase 3

Filed

Closed Triple (FF/UMEC/VI): Asthma

Collaborators: GSK & Innoviva, Inc.²

Phase 1

Phase 2

Phase 3

MABA, MABA/ICS (batefenterol, batefenterol/FF): COPD

Collaborators: GSK & Innoviva, Inc.²

Phase 1

Phase 2

Notes:
¹ Concurrent bacteremia data added to U.S. label for approved indications (cSSSI & HABP/VABP)
² We hold economic interest in future payments that may be made by GlaxoSmithKline plc (GSK) relating to certain programs, including “Closed Triple” (FF/UMEC/VI) (Fluticasone Furoate/Umeclidinium/Vilanterol), MABA/FF (batefenterol/FF), MABA monotherapy and other future products that may be combined with VI or MABA (batenfenterol)

Key:

  • CNS: Central Nervous System
  • COPD: Chronic Obstructive Pulmonary Disease
  • cSSSI: Complicated Skin and Skin Structure Infections
  • FF: Fluticasone Furoate
  • GI: Gastrointestinal
  • HABP/VABP: Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia
  • HCV: Hepatitis C Virus
  • ICS: Inhaled Corticosteriod
  • MABA: Bifunctional Muscarinic Antagonist-Beta2 Agonist
  • MRSA: Methicillin-Resistant Staphylococcus Aureus
  • nOH: Neurogenic Orthostatic Hypotension
  • OIC: Opioid-Induced Constipation
  • UMEC: Umeclidinium
  • VI: Vilanterol

In the table above:

  • Status indicates the most advanced stage of clinical development that has been completed or is in process.
  • Phase 1 indicates initial clinical safety testing in healthy volunteers, or studies directed toward understanding the mechanisms of action of the drug.
  • Phase 2 indicates further clinical safety testing and preliminary efficacy testing in a limited patient population.
  • Phase 3 indicates evaluation of clinical efficacy and safety within an expanded patient population.
  • Filed indicates that a marketing application has been submitted to a regulatory authority.